Results 61 to 70 of about 69,722 (292)

The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Polypharmacy is increasingly recognized as a relevant issue in diabetes care, but its prevalence and clinical relevance in individuals with type 1 diabetes remain underexplored. This study aimed to determine the prevalence of polypharmacy and to identify associated clinical and psychological factors. Participants were recruited from a tertiary diabetes
Namam Ali   +4 more
wiley   +1 more source

A comparative study of fasting, postprandial blood glucose and glycated hemoglobin for diagnosing diabetes mellitus in staff members of MMIMSR, Mullana, Ambala

open access: yesMedical Journal of Dr. D.Y. Patil University, 2015
Introduction: For decades, the diagnosis of diabetes mellitus was based on blood glucose criteria, either the fasting blood glucose (FBG) or a 2-h value in the 75-g oral glucose tolerance test.
Qazi Najeeb   +3 more
doaj   +1 more source

Streptozotocin induced hyperglycemia in the axolotl

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background Diabetes is a group of diseases characterized by loss of β cell mass and/or function, resulting in hyperglycemia. With no established curative treatment, this has initiated research in β cell regeneration. Current animal models have either limited regenerative capacity (mice) or small size and evolutionary distance from humans ...
Pernille Lajer Sørensen   +2 more
wiley   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou   +7 more
wiley   +1 more source

Associations of glycated hemoglobin with hemoglobin levels and erythrocyte parameters

open access: yesMìžnarodnij Endokrinologìčnij Žurnal
Background. In patients with diabetes mellitus, pathologic changes occur in multiple organs and systems, the pathogenesis of which involves inflammatory reactions. The chronic inflammatory process can lead to the development of anemia. Several changes in
Ye.I. Dzis   +3 more
doaj   +1 more source

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori   +5 more
wiley   +1 more source

Labile hemoglobin A1c: a factor affecting the estimation of glycated hemoglobin [PDF]

open access: yesJournal of Clinical and Experimental Investigations, 2017
Labile hemoglobin A1c (also known as pre-HbA1c or LA1c or pre-glycohemoglobin) an unstable form, is a Schiff base formed during non-enzymatic glycation of hemoglobin. The concentration of labile fraction varies with acute change in plasma glucose level. Labile hemoglobin A1c fraction cannot be separated from the stable ketoamine fraction by most of the
SİNGH, Kalpana   +3 more
openaire   +2 more sources

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller   +8 more
wiley   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy